Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Jose Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gomez, Phuong Dinh, Karine Kauria, Veerie Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horvath, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Gunz, Joo Hyuk Sohn, Vladimir SemiglazovGuillermo Lerzo, Marketa Palacova, Volodymur Probachai, Lajos Pusztai

    Research output: Contribution to journalArticle

    861 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)663-640
    JournalThe Lancet
    Volume379
    Issue number9816
    DOIs
    Publication statusPublished - 2012

    Cite this

    Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., ... Pusztai, L. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet, 379(9816), 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3